Lifestyle

Cash balance pension plans for medical groups present the opportunity to rev up retirement plan contributions, which caused a huge amount of interest in them starting 10 years ago.

An IRS summons just went out to an attorney fashioned as an expert in Captive Insurance Companies. Although it's not clear what the summons is for, physicians and advisors should be aware.

Everything in life worth achieving requires practice. In fact, life itself is nothing more than one long practice session, an endless effort of refining our motions

The science of creating the perfect tweet may have finally been discovered and it's really not as difficult as you would think.

The biotech industry is stable for now, but it won't be able to rely on big pharma for much buyouts in the next few years.

A common estate planning mistake could mean your beneficiaries could contradict and even supersede certain instructions in your will.

Malpractice is a threat that ever hangs over the heads of physicians, so get in front and take the right precautions to prevent a case.

Dubrovnik has an interesting history of physicians and the relationships they had with patients.

Americans are feeling distinctly out of control when it comes to their efforts to maintain or build retirement savings.

A new set of computer models designed to predict the side effects of current and experimental drugs holds the potential to improve drug development and patient treatment.

This is the end of the road for Infinity Pharmaceuticals' cancer drug saridegib. After the company shut down two failed studies of the drug, it announced that there were no more studies planned for saridegib.

The concept of telemedicine is catching on - not just as a way for patients in rural areas to connect with physicians, but as a means for physicians to grow their practices by expanding their reach.

Since the recession began in 2008, states have been struggling to balance their budgets, which often lead to tax increases.

In the run up to next week's FDA decision on Arena Pharmaceuticals' weight-loss drug, investors have been sending the biotech's stock up.

After five years of audits to discover Medicaid fraud, $102 million were spent to find only $20 million in overpayments.

Even though the IRS has taken action several times to kill 419 plans, you should beware that they are still being promoted.

Post-death identity theft; social media habits of the wealthy; and one thing that makes it seem like saving twice for retirement.

Regeneron hasn't regained its footing since a rival eye drug combo worked in a trial.

Of the major emerging markets, only China and India have shown an increase over the past few years with the satisfaction of personal health. Russians are the least satisfied.

Old Galle is the best preserved colonial town in Sri Lanka and its history is complex; however, few Americans get to it because Sri Lanka is so far.

Real asset private placement investments can replace some of your Wall Street investments while still maintaining a diversified portfolio.

A vacation can turn into sour very quickly if you discover you've become the victim of identity theft or a scam.

A female physician researcher might find the idea of a $12,194 raise enticing, and she would only have to do one thing: swap genders.

The student loan debt bomb is understandably worrisome, but medical students have less to be concerned about.

The "sell in May" part may be easy. But the then investors have to wonder, "and go where, exactly?"

What you can do now to protect yourself against any future estate tax increases.

Eli Lilly & Co. is taking a shot at Sanofi with a new drug that matches Sanofi's Lantus at controlling blood sugar, but also helps patients lose weight.

Americans working full time or part time had healthier habits than people who were unemployed. And the healthiest group of all was those people not in the workforce.

Before you hire a financial advisor to help you with your financial planning and investments, give some thought to what you are really looking for.

Don't be taken in when an analyst says, "Buy." Even if they believe it, there are other factors and conflicts you should be aware of.